This site is intended for healthcare professionals only
LoginRegister
Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP SecretaryIndian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP...
AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITCAstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC
Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancerEli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer
NPPA fixes Special Ceiling Price for Gufics Meropenem Dual Chamber BagsNPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags
Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDCSun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin...
USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand DiseaseUSFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand...
Roche receives EU CE mark for Contivue for neovascular age-related macular degenerationRoche receives EU CE mark for Contivue for neovascular age-related macular degeneration
Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and MetoclopramideDrug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide
Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight managementVirchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management
SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma FreebiesSC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies
Dr Reddys Labs API Mirfield facility gets 7 USFDA observationsDr Reddy's Labs API Mirfield facility gets 7 USFDA observations
CDSCO Panel Rejects Theon Pharmas Proposal for Empagliflozin, Linagliptin, Metformin FDCCDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC
X